Ignite Creation Date:
2024-05-05 @ 5:20 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00437164
Status:
TERMINATED
Last Update Posted:
2012-06-04
First Post:
2007-02-16
Brief Title:
A Study To Assess GW677954 Used In Combination With Insulin In Subjects Who Have Type 2 Diabetes Mellitus
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Randomized Double-blind Parallel Placebo-Controlled Study to Evaluate the Safety and Tolerability of Oral GW677954 Capsules 15 mg in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus
Status:
TERMINATED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Company decision not related to safety
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Many drugs used for the treatment of Type 2 Diabetes Mellitus cause the body to retain water This study will assess whether or not GW677954 causes the body to retain fluid
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None